OraSure Technologies, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing, not a standalone fourth-quarter report. Amounts are in U.S. dollars unless otherwise stated.
Business context
OraSure operates two segments: Diagnostics, including rapid HIV and HCV tests and other diagnostic products, and Molecular Solutions, including sample-collection kits and microbiome laboratory services. COVID-19 collection-kit sales became a significant new revenue source in 2020. The company acquired UrSure in July 2020 and sold its cryosurgical systems business in 2019.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $171.7 million | $154.6 million |
| Gross profit / margin | $101.9 million / 59% | $94.6 million / 61% |
| Operating income (loss) | $(5.2) million | $18.6 million |
| Net income (loss) | $(14.9) million | $16.7 million |
| Diluted earnings (loss) per share | $(0.22) | $0.27 |
| Cash provided by operating activities | $5.8 million | $9.8 million |
| Cash, cash equivalents and available-for-sale securities | $257.1 million | $189.8 million |
| Working capital | $242.4 million | $191.8 million |
- Revenue mix: Diagnostics revenue was approximately $65.2 million, down 17%; Molecular Solutions revenue was approximately $106.5 million, up 39%. Molecular Solutions included $49.8 million of COVID-19-related collection-device sales.
- Segment operating results: Diagnostics recorded a $43.2 million operating loss, compared with $0.2 million operating income in 2019. Molecular Solutions operating income rose to $38.0 million from $18.5 million.
- Cash uses and funding: Capital expenditures were $26.7 million, principally for added manufacturing capacity. The company raised approximately $95.0 million net through a public stock offering of 9.2 million shares.
- Debt and liquidity: The balance sheet reports no conventional borrowings. Lease liabilities totaled approximately $6.1 million; acquisition-related contingent consideration was $2.5 million. Management said cash and investments were expected to fund foreseeable operating and capital needs. About $99.4 million of cash and investments was held by the Canadian subsidiary.
Material changes versus 2019
- Revenue increased 11%, driven by COVID-19 collection-kit sales, higher international HIV self-test sales and higher laboratory-services revenue. These gains were partly offset by lower genomics, microbiome, HCV, domestic HIV and risk-assessment sales.
- Genomics revenue fell 34% to $37.1 million, reflecting order timing and weaker testing, including changes in purchasing patterns by a major customer. COVID-19-related collection products accounted for 47% of Molecular Solutions segment revenue.
- Gross margin declined by two percentage points. Management cited lower labor utilization, increased scrap and spoilage, and lower other revenue, partly offset by product mix.
- The company swung from net income to a net loss. Increased COVID-19 product-development spending, staffing costs and acquired-business expenses contributed; 2019 results also included a $10.1 million gain on the cryosurgical business sale.
- Inventory increased to $31.9 million from $23.2 million, while operating cash flow declined. Cash and investments nevertheless rose, supported in significant part by the 2020 equity offering.
Outlook, commentary, risks and unusual items
- COVID-19 products: OraSure reported completing development and clinical data collection for professional and prescription self-test versions of its rapid antigen test, with EUA submissions expected in Q1 2021; timing and authorization remain subject to FDA review. The antibody ELISA submission required additional studies and was to be resubmitted. The filing also describes planned manufacturing-capacity additions, but does not provide a firm revenue forecast.
- Demand and capacity risk: Management cautioned that COVID-19 testing demand could fall as the pandemic subsides, while also noting risk that capacity, suppliers or materials may be insufficient to meet demand. Planned capacity expansion could be underused if commercialization or demand disappoints.
- Other business risks: The company identified continued weakness in ancestry genomics, customer and distributor concentration, pricing competition, dependence on public funding, regulatory/EUA uncertainty, and reliance on sole-source suppliers. International sales were 24% of revenue, down from 31% in 2019.
- Tax and unusual items: Income tax expense was $11.4 million despite a $3.5 million pretax loss, primarily reflecting foreign taxes; the company maintained a full valuation allowance against U.S. deferred tax assets. 2020 also included a $1.1 million noncash gain from remeasurement of contingent consideration and $393,000 of UrSure acquisition costs.
- Contingencies: A patent-related arbitration involving Ancestry remained unresolved after a new proceeding was initiated in 2020; management said ordinary-course legal matters were not expected to materially affect financial position or results. Noncancelable purchase commitments totaled $16.6 million, mostly due in 2021.
- Capital allocation: OraSure said it did not expect to pay cash dividends in the foreseeable future. Management reported effective disclosure controls and internal control over financial reporting; UrSure was excluded from the 2020 internal-control assessment pending integration.
Important facts for investors to verify
- Whether FDA authorizations for the COVID-19 antigen and antibody products were obtained, and whether planned launches and capacity additions translated into sales and returns on investment.
- How quickly COVID-19-related collection-kit demand changes, and whether the business can offset any decline through non-COVID genomics, diagnostics and laboratory services.
- Whether genomics revenue stabilizes after the major customer’s order and purchasing changes, and how customer concentration evolves.
- Whether Diagnostics segment profitability improves from its 2020 operating loss, including the effects of product mix, utilization, scrap and development spending.
- Inventory quality and sell-through, working-capital conversion, and the use of cash raised through the stock offering; also consider the tax implications of cash held in Canada.
- Progress and outcomes in the Ancestry arbitration, acquisition integration, and any material changes to contingent obligations or supplier availability.